Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Low Grade Serous Ovarian Cancer × Letrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 84 Polycystic Ovary Syndrome 9 Neoplasm Metastasis 6 Carcinoma, Ductal, Breast 5 Carcinoma, Lobular 4 Neoplasms, Hormone-Dependent 3 Neoplasms 3 Infertility 3 Osteoporosis 2 Fallopian Tube Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Breast Neoplasms, Male 2 Breast Carcinoma In Situ 2 Advanced Breast Cancer 2 Unilateral Breast Neoplasms 1 Recurrence 1 Peritoneal Neoplasms 1 Ovarian Neoplasms 1 Osteitis Deformans 1 Obesity 1 Neoplasms by Site 1 Multiple Endocrine Neoplasia Type 1 1 Low Grade Serous Ovarian Cancer 1 Infertility, Female 1 Hereditary Sensory and Autonomic Neuropathies 1 HER2+ Breast Cancer 1 Endometrial Neoplasms 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Diseases 1 Breast Cancer Metastatic 1

Interventions

liposomal doxorubicin 1 defactinib 1 Paclitaxel 1 Letrozole 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06072781 2026-03-17

RAMP 301

Verastem, Inc.

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡